- Simtuzumab and Liraglutide
- GFT 505
- Vitamin E
- Obeticholic Acid (INT-747)
- Pioglitazone
- Others
Nonalcoholic Steatohepatitis (NASH) Treatment Market size was valued at USD 1,352.1 million in 2022 and is poised to grow at a CAGR of 36.3% from 2023 to 2029. Nonalcoholic steatohepatitis (NASH) treatment or fatty liver disease develop in the nonalcoholic humans that causes the liver damage which is diagnostically similar to alcoholic hepatitis. Nonalcoholic steatohepatitis may also causes due to glucose intolerance, dyslipidemia, and obesity. Currently a few drugs are available in the market for the treatment of nonalcoholic steatohepatitis treatment. The non-alcoholic steatohepatitis (NASH) market is estimated to rise by double digits over the forecast period, owing to rising demand for optimum NASH therapies, an increase in the prevalence of NASH, and the planned launch of pipeline medications. Furthermore, an increase in the prevalence of diabetes and obesity, as well as increased awareness of NASH in developing regions, is expected to boost market growth during the forecast period. However, the industry is expected to be constrained by poor disease diagnosis and a lack of ideal diagnostic techniques. The leading players in the non-alcoholic steatohepatitis (NASH) industry will find profitable prospects in Asia-Pacific. Growth in diagnostic techniques, rapid rise in prevalence of NASH, economic expansion, and increased demand for NASH therapies are some of the factors driving market growth in Asia-Pacific. Other factors such as rising healthcare infrastructure, emerging economies, and an increasing rate of diagnosis are likely to aid the expansion of the Asia-Pacific nonalcoholic steatohepatitis (NASH) treatment market. Furthermore, rising healthcare awareness in emerging nations such as India and China is propelling the industry forward.
Nonalcoholic Steatohepatitis Nash Treatment Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
36.3%
Largest Market
North America
Fastest Growing Market
Europe
Nonalcoholic Steatohepatitis (NASH) Treatment Market Dynamics Dynamics
Increase in the prevalence of metabolic disorders such as diabetes and dyslipidemia are expected to drive the NASH Treatment Market. Moreover, rise in R&D for the innovation of novel therapeutics for NASH disease, promising pipeline products, and change in lifestyle are anticipated to boost the nonalcoholic steatohepatitis treatment market over the forecast period. However, lack of efficient disease diagnosis procedures in early stage, poor understanding of disease pathophysiology, and large medical unmet need may impede the growth of nonalcoholic steatohepatitis market.
North-America got significant share
Nonalcoholic Steatohepatitis (NASH) Treatment Market Regional Analysis
Geographically, global nonalcoholic steatohepatitis (NASH) treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America nonalcoholic steatohepatitis (NASH) treatment market growth driven by increase in the prevalence of NASH disease due to rise in obesity and metabolic disorders (according to American Liver Foundation, approximately 12% of total population has NASH and 3% has advanced liver fibrosis due to NASH) and change in lifestyle are anticipated to fuel the market. Europe nonalcoholic steatohepatitis (NASH) treatment market expected to exhibit lucrative growth due to increase in the R&D for the innovation of newer drugs, rise in prevalence of NASH due to metabolic disorders, and increase in healthcare expenditure. However, a significant growth rate observed in Asia Pacific nonalcoholic steatohepatitis (NASH) treatment market owing to entry of market players into Asia Pacific region, large patient pool, and rise in healthcare expenditure are expected to bolster the market in the region.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup’s details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Nonalcoholic Steatohepatitis Nash Treatment Market Segmentation
By Product Type
By Distribution Channel
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
Frequently Asked Questions
Based on product type, the Vitamin E and Pioglitazone (Off-label) segment dominated the NASH treatment market in 2021 attributed to the unavailability of approved drugs in the market.
Obesity and type 2 diabetes are directly linked with increased chances of NASH.
The global non-alcoholic steatohepatitis treatment market size is expected to be valued at USD 1,352.1 million in 2021.
| 1. Executive Summary |
| 2. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market Introduction |
| 2.1.Global Nonalcoholic Steatohepatitis (NASH) Treatment Market - Taxonomy |
| 2.2.Global Nonalcoholic Steatohepatitis (NASH) Treatment Market - Definitions |
| 2.2.1.Product Type |
| 2.2.2.Distribution Channel |
| 2.2.3.Region |
| 3. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market Analysis, 2018 - 2022 and Forecast 2023 - 2029 |
| 4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market By Product Type, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 5.1. Simtuzumab and Liraglutide |
| 5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. GFT 505 |
| 5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Vitamin E |
| 5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Obeticholic Acid (INT-747) |
| 5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Pioglitazone |
| 5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. Others |
| 5.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 6. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market By Distribution Channel, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 6.1. Hospital Pharmacies |
| 6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Online Pharmacies |
| 6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Retail Pharmacies |
| 6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia Pacific (APAC) |
| 7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Middle East and Africa (MEA) |
| 7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Latin America |
| 7.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 8. North America Nonalcoholic Steatohepatitis (NASH) Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 8.1. Product Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1.Simtuzumab and Liraglutide |
| 8.1.2.GFT 505 |
| 8.1.3.Vitamin E |
| 8.1.4.Obeticholic Acid (INT-747) |
| 8.1.5.Pioglitazone |
| 8.1.6.Others |
| 8.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.2.1.Hospital Pharmacies |
| 8.2.2.Online Pharmacies |
| 8.2.3.Retail Pharmacies |
| 8.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.3.1.United States of America (USA) |
| 8.3.2.Canada |
| 9. Europe Nonalcoholic Steatohepatitis (NASH) Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 9.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Simtuzumab and Liraglutide |
| 9.1.2.GFT 505 |
| 9.1.3.Vitamin E |
| 9.1.4.Obeticholic Acid (INT-747) |
| 9.1.5.Pioglitazone |
| 9.1.6.Others |
| 9.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Hospital Pharmacies |
| 9.2.2.Online Pharmacies |
| 9.2.3.Retail Pharmacies |
| 9.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Germany |
| 9.3.2.France |
| 9.3.3.Italy |
| 9.3.4.United Kingdom (UK) |
| 9.3.5.Spain |
| 9.3.6.Rest of EU |
| 10. Asia Pacific (APAC) Nonalcoholic Steatohepatitis (NASH) Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 10.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Simtuzumab and Liraglutide |
| 10.1.2.GFT 505 |
| 10.1.3.Vitamin E |
| 10.1.4.Obeticholic Acid (INT-747) |
| 10.1.5.Pioglitazone |
| 10.1.6.Others |
| 10.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Hospital Pharmacies |
| 10.2.2.Online Pharmacies |
| 10.2.3.Retail Pharmacies |
| 10.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.China |
| 10.3.2.India |
| 10.3.3.Australia and New Zealand (ANZ) |
| 10.3.4.Japan |
| 10.3.5.Rest of APAC |
| 11. Middle East and Africa (MEA) Nonalcoholic Steatohepatitis (NASH) Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 11.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Simtuzumab and Liraglutide |
| 11.1.2.GFT 505 |
| 11.1.3.Vitamin E |
| 11.1.4.Obeticholic Acid (INT-747) |
| 11.1.5.Pioglitazone |
| 11.1.6.Others |
| 11.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Hospital Pharmacies |
| 11.2.2.Online Pharmacies |
| 11.2.3.Retail Pharmacies |
| 11.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.GCC Countries |
| 11.3.2.South Africa |
| 11.3.3.Rest of MEA |
| 12. Latin America Nonalcoholic Steatohepatitis (NASH) Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 12.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Simtuzumab and Liraglutide |
| 12.1.2.GFT 505 |
| 12.1.3.Vitamin E |
| 12.1.4.Obeticholic Acid (INT-747) |
| 12.1.5.Pioglitazone |
| 12.1.6.Others |
| 12.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Hospital Pharmacies |
| 12.2.2.Online Pharmacies |
| 12.2.3.Retail Pharmacies |
| 12.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Brazil |
| 12.3.2.Mexico |
| 12.3.3.Rest of LA |
| 13. Competition Landscape |
| 13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 13.2.1.Zydus Cadila (India) |
| 13.2.2.Genfit SA (France) |
| 13.2.3.AstraZeneca Plc (UK) |
| 13.2.4.Gilead Sciences, Inc. (U.S.) |
| 13.2.5.Conatus Pharmaceuticals, Inc. (U.S.) |
| 13.2.6.Galmed Pharmaceuticals Ltd (Israel) |
| 14. Research Methodology |
| 15. Appendix and Abbreviations |
- Zydus Cadila (India)
- Genfit SA (France)
- AstraZeneca Plc (UK)
- Gilead Sciences, Inc. (U.S.)
- Conatus Pharmaceuticals, Inc. (U.S.)
- Galmed Pharmaceuticals Ltd (Israel)
- Immuron (Australia)
- Intercept Pharmaceuticals, Inc. (U.S.)
- Tobira Therapeutics, Inc. (U.S.)
- Galectin Therapeutics, Inc. (U.S)